A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity

An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology

Paolo Spallarossa, Nicola Maurea, Christian Cadeddu, Rosalinda Madonna, Donato Mele, Ines Monte, Giuseppina Novo, Pasquale Pagliaro, Alessia Pepe, Carlo G. Tocchetti, Concetta Zito, Giuseppe Mercuro

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to the cardiologist who has not accumulated much experience in the field of cancer therapy, focuses on several topics, that is old and new mechanisms of cardiac toxicity, late cardiac toxicity, the importance of overall risk assessment, the key role of a cardiology consult before starting cancer therapy, and the pros and cons of primary and secondary prevention programmes.

Original languageEnglish
Pages (from-to)S84-S92
JournalJournal of Cardiovascular Medicine
Volume17
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Anthracyclines
Cardiology
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Hematologic Neoplasms
Primary Prevention
Therapeutics
Secondary Prevention
Cardiomyopathies
Cardiotoxicity
Cardiologists
Oncologists

Keywords

  • anthracyclines
  • cardio-oncology
  • cardiology consult
  • cardiotoxicity
  • heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity : An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. / Spallarossa, Paolo; Maurea, Nicola; Cadeddu, Christian; Madonna, Rosalinda; Mele, Donato; Monte, Ines; Novo, Giuseppina; Pagliaro, Pasquale; Pepe, Alessia; Tocchetti, Carlo G.; Zito, Concetta; Mercuro, Giuseppe.

In: Journal of Cardiovascular Medicine, Vol. 17, 01.05.2016, p. S84-S92.

Research output: Contribution to journalArticle

Spallarossa, Paolo ; Maurea, Nicola ; Cadeddu, Christian ; Madonna, Rosalinda ; Mele, Donato ; Monte, Ines ; Novo, Giuseppina ; Pagliaro, Pasquale ; Pepe, Alessia ; Tocchetti, Carlo G. ; Zito, Concetta ; Mercuro, Giuseppe. / A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity : An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. In: Journal of Cardiovascular Medicine. 2016 ; Vol. 17. pp. S84-S92.
@article{9ffeb0fae3c94f4183b007644debdbd1,
title = "A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology",
abstract = "Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to the cardiologist who has not accumulated much experience in the field of cancer therapy, focuses on several topics, that is old and new mechanisms of cardiac toxicity, late cardiac toxicity, the importance of overall risk assessment, the key role of a cardiology consult before starting cancer therapy, and the pros and cons of primary and secondary prevention programmes.",
keywords = "anthracyclines, cardio-oncology, cardiology consult, cardiotoxicity, heart failure",
author = "Paolo Spallarossa and Nicola Maurea and Christian Cadeddu and Rosalinda Madonna and Donato Mele and Ines Monte and Giuseppina Novo and Pasquale Pagliaro and Alessia Pepe and Tocchetti, {Carlo G.} and Concetta Zito and Giuseppe Mercuro",
year = "2016",
month = "5",
day = "1",
doi = "10.2459/JCM.0000000000000381",
language = "English",
volume = "17",
pages = "S84--S92",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity

T2 - An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology

AU - Spallarossa, Paolo

AU - Maurea, Nicola

AU - Cadeddu, Christian

AU - Madonna, Rosalinda

AU - Mele, Donato

AU - Monte, Ines

AU - Novo, Giuseppina

AU - Pagliaro, Pasquale

AU - Pepe, Alessia

AU - Tocchetti, Carlo G.

AU - Zito, Concetta

AU - Mercuro, Giuseppe

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to the cardiologist who has not accumulated much experience in the field of cancer therapy, focuses on several topics, that is old and new mechanisms of cardiac toxicity, late cardiac toxicity, the importance of overall risk assessment, the key role of a cardiology consult before starting cancer therapy, and the pros and cons of primary and secondary prevention programmes.

AB - Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to the cardiologist who has not accumulated much experience in the field of cancer therapy, focuses on several topics, that is old and new mechanisms of cardiac toxicity, late cardiac toxicity, the importance of overall risk assessment, the key role of a cardiology consult before starting cancer therapy, and the pros and cons of primary and secondary prevention programmes.

KW - anthracyclines

KW - cardio-oncology

KW - cardiology consult

KW - cardiotoxicity

KW - heart failure

UR - http://www.scopus.com/inward/record.url?scp=84969945010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969945010&partnerID=8YFLogxK

U2 - 10.2459/JCM.0000000000000381

DO - 10.2459/JCM.0000000000000381

M3 - Article

VL - 17

SP - S84-S92

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

ER -